202 results about "Uricacidemia" patented technology

The invention relates to application of a stilbene derivative and pharmaceutically acceptable salts thereof to preparation of medicines or health-care products for preventing and/or treating hyperuricemia, and acute gout, chronic gout, gouty arthritis, gout attack, uric acid nephrolithiasis and gouty nephropathy caused by the hyperuricemia. The stilbene derivative is used as an active component for preparing the medicines for treating the hyperuricemia, can reduce the concentration of uric acid in blood, has a significant effect on treatment of the hyperuricemia, does not have toxic or side effects and has good safety.

The invention discloses lactobacillus gasseri and application thereof in relieving and treating hyperuricemia, and belongs to the technical field of microorganisms. According to the lactobacillus gasseri CCFM1133 disclosed by the invention, the serum uric acid level of hyperuricemia mice and the xanthine oxidase (XOD) activity of serum and a liver can be reduced, and the occurrence of hyperuricemia and gout is reduced; the blood glucose and serum triglyceride (TG) level of a patient with hyperuricemia can be regulated, and the activity of liver catalase (CAT) and glutathione peroxidase (GSH-Px) is improved; expression of ileum ABCG2 is improved, and excretion of intestinal uric acid is promoted; and the intestinal short-chain fatty acid level is improved, and the health is promoted. The lactobacillus gasseri CCFM1133 disclosed by the invention can be used for preparing foods, functional foods or medicines, and has a wide application prospect.

Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).

The invention discloses novel medicinal application of coreopsis tinctoria, and particularly relates to application of coreopsis tinctoria extract to preparing medicines for treating hyperuricemia. The novel medicinal application has the advantages that effects of treating the hyperuricemia can be realized by the coreopsis tinctoria extract, the concentration of uric acid in blood can be effectively reduced, and excellent curative effects can be realized for metabolic diseases such as acute gout, chronic gout, gouty arthritis, gout flare, uric acid renal lithiasis and gouty nephropathy which are relevant to the hyperuricemia.

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

The invention discloses application of Gynura procumbens to the production of medicine, healthcare food or functional food for preventing and treating hyperuricemia. Evidence is provided to show that the Gynura procumbens has an evident effect of preventing and treating the hyperuricemia, can lower the serum uric acid value of a patient with the hyperuricemia, has an evident uric acid lowering effect and is capable of relieving the clinical symptoms of the patient with the hyperuricemia.

The invention discloses a plant composition for treating hyperuricemia and gout and plant composition solid granules. The plant composition is prepared from celery seed extract, corn silk powder, pumpkin powder, lotus leaf powder, mulberry powder, ginseng powder grape powder by mixing. The plant composition solid granules are mainly prepared from the plant composition. According to the plant composition for treating the hyperuricemia and the gout and the plant composition solid granules, the celery seed extract, the corn silk powder, the pumpkin powder, the lotus leaf powder, the mulberry powder, the ginseng powder and the grape powder are compounded for use to improve the nutritional compositions, and the celery seed extract can significantly reduce the serum uric acid level and the urineuric acid level of the hyperuricemia; the corn silk powder and the lotus leaf powder can accelerate urinary excretion and help uric acid excretion; and the pumpkin powder, the mulberry powder, the ginseng powder and the grape powder have the functions of nourishing the liver and kidney, enhancing immunity and protecting the liver and kidney. The action mechanism of each component is different, multi-component mixing effectively exerts the synergistic effect between the components, the action time is prolonged, the curative effect is enhanced, and the components are homologous to medicine andfood, are safe and have no side effects.

The invention relates to a medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof, which is prepared from cassia seed, plantain herb, ligustrum japonicum, black-tail snake, wasp's nest, and gynostemma pentaphylla. The invention also relates to the process for preparing various preparations of the medicament.

The invention relates to an ampelopsis grossedentata leaf and herba cichorii composition and a preparation method thereof and application of the composition. The ampelopsis grossedentata leaf and herba cichorii composition consists of ampelopsis grossedentata leaves, herba cichorii, fructus gardeniae, folium mori, radix puerariae and bulbus lilii. The composition of the invention takes medicinal and edible medicinal materials as raw materials; according to the theory of traditional Chinese medicine, medicine properties and dosage, the composition is reasonably proportioned, keeps pathogenesis,and performs treatment based on syndrome differentiation, and has a significant treatment effect on damp-heat blockage type uricemia (symptoms including proteinuria, hematuresis, edema, uric acid calculus, glucose and lipid metabolism disorder and the like). In addition, the prescription of the invention has no toxic and side effects, is safe and reliable, and is convenient to take.

The invention provides a recombinant adeno-associated virus mediated hyperuricemia treatment medicine. A recombinant adeno-associated virus carrier carries an artificially designed urate oxidase geneexpression frame. In-vivo experiment shows that the recombinant adeno-associated virus carrier can be efficiently led into a body, then urate oxidase can be continuously and stably expressed, the content of uric acid can be reduced, and gout symptoms caused by excessive uric acid in blood can be effectively relieved. Results show that the recombinant adeno-associated virus carrier has the potential of being developed into a novel hyperuricemia treatment medicine.